Humanetics is a new breed of specialty pharmaceutical company focused on discovery, development and commercialization of proprietary, orally-administered, bioactive compounds for disease prevention. The Company has an extensive patent portfolio and an active pipeline of compounds that range from discovery phase to human clinical trials. The company is focused on three large biotherapeutic areas with urgent and unmet needs including immunodeficiency disorders, neurodegenerative diseases and metabolic dysfunction. Current disease targets within these biotherapeutic areas include Acute Radiation Syndrome (ARS), antibiotic resistant bacteria, Alzheimer’s disease, obesity and cardiovascular disease.